27456016|t|Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma
27456016|a|Fibrolamellar carcinoma (FLC) and conventional hepatocellular carcinoma (HCC) share the same American Joint Committee on Cancer (AJCC) staging. The worse survival with HCC is attributed to the underlying cirrhosis .The aim of this study was to compare stage-matched prognosis after resection of FLC and non-cirrhotic HCC. Outcomes after resection of 65 consecutive patients with FLC and 158 non-cirrhotic patients with HCC were compared. Patients were staged according to the 7th edition AJCC staging. The AJCC stage distributions for FLC and HCC demonstrated a predominance of stage IV disease in FLC and stage I in HCC (FLC stage I-23 %, II-15 %, III-15 %, IV-46 % vs. HCC stage I-42 %, II-32 %, III-20 %, IV-6 %, p < 0.001). Among stage IV FLC patients, 81 % had isolated nodal metastases, which did not affect overall survival (OS) or recurrence-free survival (RFS). In FLC, OS was significantly affected by the number of tumors and vascular invasion (p < 0.05). Recurrent disease developed in 56 (86 %) FLC patients and was treated with repeat surgical resection in 25 (45 %) patients. Vascular invasion was associated with recurrent FLC, with 3-year RFS rates of 9 % and 35 %, with and without vascular invasion (p = 0.034). With respect to RFS, the AJCC staging did not stratify FLC patients, compared to non-cirrhotic HCC. When compared to non-cirrhotic HCC, patients with FLC are not adequately stratified by AJCC staging with respect to RFS. Our results support classifying lymph node metastases in FLC as regional disease, rather than systemic disease. Important prognostic factors in FLC are the number of tumors and vascular invasion.
27456016	0	9	Prognosis	T058	UMLS:C0033325
27456016	13	36	Fibrolamellar Carcinoma	T038	UMLS:C0334287
27456016	76	100	Hepatocellular Carcinoma	T038	UMLS:C2239176
27456016	101	124	Fibrolamellar carcinoma	T038	UMLS:C0334287
27456016	126	129	FLC	T038	UMLS:C0334287
27456016	148	172	hepatocellular carcinoma	T038	UMLS:C2239176
27456016	174	177	HCC	T038	UMLS:C2239176
27456016	194	228	American Joint Committee on Cancer	T092	UMLS:C1515946
27456016	230	234	AJCC	T092	UMLS:C1515946
27456016	236	243	staging	T170	UMLS:C0441915
27456016	269	272	HCC	T038	UMLS:C2239176
27456016	305	314	cirrhosis	T038	UMLS:C0023890
27456016	353	366	stage-matched	T201	UMLS:C1300072
27456016	367	376	prognosis	T058	UMLS:C0033325
27456016	383	392	resection	T058	UMLS:C0015252
27456016	396	399	FLC	T038	UMLS:C0334287
27456016	418	421	HCC	T038	UMLS:C2239176
27456016	438	447	resection	T058	UMLS:C0015252
27456016	480	483	FLC	T038	UMLS:C0334287
27456016	520	523	HCC	T038	UMLS:C2239176
27456016	553	559	staged	T201	UMLS:C1300072
27456016	589	601	AJCC staging	T170	UMLS:C0441915
27456016	607	631	AJCC stage distributions	T170	UMLS:C0441915
27456016	636	639	FLC	T038	UMLS:C0334287
27456016	644	647	HCC	T038	UMLS:C2239176
27456016	679	695	stage IV disease	T201	UMLS:C1300072
27456016	699	702	FLC	T038	UMLS:C0334287
27456016	707	714	stage I	T201	UMLS:C1300072
27456016	718	721	HCC	T038	UMLS:C2239176
27456016	723	726	FLC	T038	UMLS:C0334287
27456016	727	732	stage	T201	UMLS:C1300072
27456016	772	775	HCC	T038	UMLS:C2239176
27456016	776	781	stage	T201	UMLS:C1300072
27456016	835	843	stage IV	T201	UMLS:C1300072
27456016	844	847	FLC	T038	UMLS:C0334287
27456016	876	881	nodal	T082	UMLS:C0443268
27456016	882	892	metastases	T038	UMLS:C0027627
27456016	940	964	recurrence-free survival	T033	UMLS:C2919733
27456016	966	969	RFS	T033	UMLS:C2919733
27456016	975	978	FLC	T038	UMLS:C0334287
27456016	1038	1055	vascular invasion	T033	UMLS:C0521157
27456016	1068	1085	Recurrent disease	T038	UMLS:C0277556
27456016	1130	1142	treated with	T058	UMLS:C0332293
27456016	1150	1168	surgical resection	T058	UMLS:C0015252
27456016	1192	1209	Vascular invasion	T033	UMLS:C0521157
27456016	1240	1243	FLC	T038	UMLS:C0334287
27456016	1257	1260	RFS	T033	UMLS:C2919733
27456016	1301	1318	vascular invasion	T033	UMLS:C0521157
27456016	1348	1351	RFS	T033	UMLS:C2919733
27456016	1357	1369	AJCC staging	T170	UMLS:C0441915
27456016	1387	1390	FLC	T038	UMLS:C0334287
27456016	1427	1430	HCC	T038	UMLS:C2239176
27456016	1463	1466	HCC	T038	UMLS:C2239176
27456016	1482	1485	FLC	T038	UMLS:C0334287
27456016	1519	1531	AJCC staging	T170	UMLS:C0441915
27456016	1548	1551	RFS	T033	UMLS:C2919733
27456016	1585	1595	lymph node	T017	UMLS:C0024204
27456016	1596	1606	metastases	T038	UMLS:C0027627
27456016	1610	1613	FLC	T038	UMLS:C0334287
27456016	1617	1633	regional disease	T033	UMLS:C1514819
27456016	1647	1663	systemic disease	T038	UMLS:C0442893
27456016	1675	1693	prognostic factors	T201	UMLS:C1514474
27456016	1697	1700	FLC	T038	UMLS:C0334287
27456016	1730	1747	vascular invasion	T033	UMLS:C0521157